Phase 3 Readout~month

Phase 3 Topline: An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futiba

Indication
Advanced/Metastatic Cancer

Other upcoming events for CGON

Phase 3 ReadoutPhase 3 Topline: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuva
Phase 3 ReadoutPhase 3 Topline: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and
Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cispla
Phase 3 ReadoutPhase 3 Topline: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futiba — CGON Phase 3 Readout | BioSniper